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Mechanical unloading by left ventricular assist devices (LVADs) in advanced heart failure (HF), in addition to improving symptoms
and end-organ perfusion, is supposed to stimulate cellular and molecular responses which can reverse maladaptive cardiac
remodeling. As microRNAs (miRNAs) are key regulators in remodeling processes, a comparative miRNA profiling in transplanted
hearts of HF patients with/without LVAD assistance could aid to comprehend underlying molecular mechanisms. Next generation
sequencing (NGS) was used to analyze miRNA differential expression in left ventricles of HF patients who underwent heart
transplantation directly (𝑛 = 9) or following a period of LVAD support (𝑛 = 8). After data validation by quantitative real-time PCR,
association with functional clinical parameters was investigated. Bioinformatics’ tools were then used for prediction of putative
targets ofmodulatedmiRNAs and relative pathway enrichment.The analysis revealed 13 upregulated and 10 downregulatedmiRNAs
in failing hearts subjected to LVAD assistance. In particular, the expression level of some of them (miR-338-3p, miR-142-5p and -3p,
miR-216a-5p, miR-223-3p, miR-27a-5p, and miR-378g) showed correlation with off-pump cardiac index values. Predicted targets
of these miRNAs were involved in focal adhesion/integrin pathway and in actin cytoskeleton regulation. The identified miRNAs
might contribute to molecular regulation of reverse remodeling and heart recovery mechanisms.
1. Introduction
MicroRNAs are highly conserved, single-stranded, noncod-
ing RNAs of about 18–24 nucleotides, which act as endog-
enous repressors of target genes, either by inhibiting trans-
lation or by promoting degradation of the mRNA [1]. An
individualmiRNAcan influence hundreds of gene transcripts
to coordinate complex programs of gene expression and,
thereby, effect global changes in the physiology of a cell
[2, 3]. Due to their extraordinary variability of expression
across tissues and physiological states, miRNAs can be
powerful diagnostic and prognostic tools in several diseases.
Accordingly, alterations in intra/extracellular miRNAs have
been correlated with various cardiovascular conditions, such
as myocardial infarction, hypertrophy, cardiomyopathy, and
arrhythmias [4].
In advanced HF, mechanical circulatory support by
LVADs may bring beneficial effects through unloading of
failing left ventricle (LV), increasing total cardiac output,
and improving general clinical condition and potentially
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quality of life. In addition, LVAD support is reported to
stimulate cellular, biochemical, and molecular changes in
the failing heart, which can result in improvements in
different aspects of myocyte functionality, such as calcium
handling, responsiveness to beta-adrenergic stimulation, and
contractile properties [5, 6]. This complexity of cellular
and molecular responses is globally referred to as “reverse
remodeling,” and it is considered to be possible mechanism
of heart function recovery, which in some cases can lead to
LVAD weaning.
Since changes in gene expression and regulation are
involved in all remodeling processes, in the last years research
has been dedicated to the investigation, at a molecular level,
ofmechanismswhich could be altered duringHFprogression
but could be also susceptible to recovery after mechanical
assistance [7–12]. AlthoughmiRNA profiling of failing hearts
with or without LVAD support has given so far contradicting
results, probably because of the different approaches used
(Q-RT PCR [7, 13], microarray [8, 11], and high-throughput
sequencing [10, 12]) and the variability of patients’ conditions,
these results support the hypothesis that microRNAs are
important players in LVAD-induced heart remodeling and
sustain further studies for the continued exploration of this
class of gene regulators.
The aimof this studywas to evaluate and comparemiRNA
expression profiling in heart tissues of advanced HF patients
undergoing cardiac transplantation directly (HTx-CTRL) or
after a period of support with LVAD as bridge to transplant
(HTx-LVAD). Next generation sequencing techniques have
been applied for a complete qualitative and quantitative
analysis of miRNA expression, in order to check possible
differentially modulated miRNAs, capable of distinguishing
the two groups of patients.
2. Materials and Methods
2.1. Study Population and Tissue Sample Collection. The study
was retrospectively performed on heart tissues collected at
the time of heart transplantation from advanced HF patients
who underwent organ transplantation directly (HTx-CTRL,
𝑛 = 9) or after a period of support with a LVAD as bridge
to transplant (HTx-LVAD, 𝑛 = 8). Patients were recruited at
the Cardiothoracic andVascular Department ofNiguarda Ca’
Granda Hospital in Milan, Italy. The study was approved by
the local ethics committee. A written informed consent was
obtained from each patient. The age of patients ranged from
18 to 65 years; the diagnosis of advanced HF (NYHA class
III-IV) was due to idiopathic dilated cardiomyopathy (IDC)
or ischemic cardiomyopathy, that is, dilated cardiomyopathy
induced by chronic ischemic heart disease with/without
history ofmyocardial infarction (IHD) (Table 1).The patients
showed an ejection fraction <35% at the moment of heart
transplantation or LVAD implantation. Exclusion criteria
were hypertrophic cardiomyopathy, dilated cardiomyopathy
secondary to genetic syndromes, fixed pulmonary hyper-
tension, irreversible renal or hepatic failure, severe diabetes
mellitus with end-organ damage, severe peripheral vascular
or cerebrovascular disease, and coexisting active neoplasm.
Hemodynamic (from right heart catheterization) and
echocardiographic parameters were derived from the clinical
database and acquired at the time of patient insertion in
the transplant list. Moreover, in the LVAD implanted group,
data were obtained twice, at LVAD implant and off-pump
(clamping outflow cannula) at the time of heart trans-
plant, immediately before native heart removal. Pretransplant
measurements derived from transthoracic echocardiography
were acquired during LVAD hemodynamic unloading. Seven
patients were supported by continuous flow LVADs: 4 by
HeartMate II LVADs (Thoratec, Pleasanton, CA), 2 by De
Bakey LVADs (MicroMed Technology, Houston, TX), and 1
by INCOR LVAD (Berlin Heart AG, Germany); one patient
received Best BEAT (NewCorTec, Pomezia, Italy) pulsatile
LVAD pump. All patients in the study were on optimal
pharmacological treatment.
In both groups of patients, tissue samples from LV
anterior or lateral basal zone were taken at the moment of
heart transplantation, immediately frozen in liquid nitrogen,
and stored at −80∘C.
2.2. RNA Extraction and miRNA Sequencing. Heart tissue
samples ranging from 30 to 120mgwere used for RNA extrac-
tion. Tissues were powdered and resuspended in QIAzol
Lysis Reagent (Qiagen). Total RNA extraction was performed
by phenol-chloroform extraction methods using miRNeasy
kit (Qiagen), according to the manufacturer’s instructions.
Quality control of total RNAs was performed with the RNA
6000 pico kit (Agilent Technologies 2100 Bioanalyzer). Small
RNA libraries were constructed with the TruSeq Small RNA
kit (Illumina), according to the manufacturer’s instructions.
Sequencing was performed using Illumina’s HiSeq 2000.
2.3. MiRNA Profiling and Differential Expression Analysis.
Raw sequences of 50 bp length were produced and demul-
tiplexed using the Illumina pipeline CASAVA v1.8. FastQC
v0.10.1 (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/) was used for quality check. Primary reads were
initially trimmed off adapter sequences using Cutadapt v.1.2.1
[14]. Remaining high quality reads, with length of 17–35 bp
after clipping, were clustered for unique hits and mapped to
known human pre-miRNA sequences from mirBase (release
20) employing miRExpress tool (v2.1.3) [15]. The 95% of
sequence identity between reads and pre-miRNA sequences
and length tolerance shifting range of 4 bp were considered
acceptable. miRNA expression profiles were built by calculat-
ing the sum of read counts for each miRNA, according to the
alignment criteria.
To inspect sample relations, variance-stabilizing trans-
formed count data were used to build an Euclidean dis-
tance matrix, followed by hierarchical clustering analysis,
as described elsewhere [16]. miRNA differential expression
analysis was performed using Bioconductor’s package DESeq
[16]. The obtained read counts for each identified miRNA
were first normalized by scaling for library size factors in
order to deal with variation among samples. An independent
filter was then used to improve the detection power of
the statistical test [17], as suggested in the DESeq vignette
[18]. Specifically, the overall sum of counts, irrespective of
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Table 1: Patient characteristics and clinical parameters.
HTx-CTRL (𝑛 = 9) HTx-LVAD (𝑛 = 8)
Pre-LVAD Post-LVAD
Age (years), mean ± SE 52 ± 3 46 ± 4 —
Male gender (𝑛) 5 8 —
Duration of LVAD assistance (days), mean ± SE — — 357 ± 66
Ischemic heart disease (IHD) (𝑛) 2 1 —
Cardiac index (L/min/m2), mean ± SE 1.90 ± 0.17 1.61 ± 0.13 2.82 ± 0.30#∗∗
PCWP (mmHg), mean ± SE 14 ± 3 24 ± 5 9 ± 3∗
PASP (mmHg), mean ± SE 33 ± 4 47 ± 6 27 ± 3∗
PADP (mmHg), mean ± SE 13 ± 2 23 ± 3‡ 12 ± 4∗
LVEF (%), mean ± SE 26 ± 2 21 ± 2 28 ± 3∗
LVESV (mL), mean ± SE 147 ± 17 282 ± 27‡ 160 ± 20∗∗
LVEDV (mL), mean ± SE 196 ± 18 357 ± 32§ 219 ± 18∗∗
LVEDD (mm), mean ± SE 66 ± 2 80 ± 3§ 70 ± 3∗
NT-proBNP (ng/L), mean ± SE 2976 ± 1562 4800 ± 991 576 ± 145∗∗
#
𝑃 < 0.05 versus HTx-CTRL; ‡𝑃 < 0.01 versus HTx-CTRL; §𝑃 < 0.001 versus HTx-CTRL; ∗𝑃 < 0.05 versus pre-LVAD; ∗∗𝑃 < 0.01 versus pre-LVAD.
PCWP: pulmonary capillary wedge pressure; PASP: pulmonary artery systolic pressure; PADP: pulmonary artery diastolic pressure; LVEF: left ventricular
ejection fraction; LVESV: left ventricular end-systolic volume; LVEDV: left ventricular end-diastolic volume; LVEDD: left ventricular end-diastolic diameter;
NT-proBNP: N-terminal prohormone of brain natriuretic peptide.
biological condition, was considered in order to remove
miRNAs in the lowest 30% quantile. 𝑃 values were estimated
using a negative binomial distribution model and local
regression to estimate the relationship between the dispersion
and the mean of each miRNA. Raw 𝑃 values, considered as
statistically significant when <0.01, were finally adjusted for
multiple testing by the Benjamini and Hochberg procedure
[19], by setting a 10% false discovery rate (FDR) threshold.
A fold change (FC) threshold of 1.6 was finally used to select
modulated miRNAs.
2.4. Validation by Quantitative Real-Time PCR. Expression
analysis of specific miRNAs was validated by quantitative
real-time (Q-RT) PCR. cDNA was obtained from 0.5𝜇g of
total RNA using the miScript II reverse transcription kit
(Qiagen). Q-RT PCR was performed with QuantiFast SYBR
Green PCRMaster Mix (Qiagen), using a Rotor Gene Q real-
time PCR cycler (Qiagen). Relative expression levels were
calculated with the comparative threshold cycle (Cq)method
[20], using snRNA U1 as reference for normalization.
2.5. Identification of Putative miRNA Targets and Path-
way Enrichment Analysis. miRNA target predictions were
obtained from TargetScan (http://targetscan.org version 6.2
human). DIANAmirPath v2.0 web-application [21] and over-
representation analysis (ORA) tool available in Consensus-
PathDB (http://cpdb.molgen.mpg.de/CPDB) [22] were uti-
lized in order to identify pathways from Kyoto Encyclopedia
of Genes and Genomes (KEGG) database (http://www.ge-
nome.jp/kegg/) enriched among the list ofmRNA targets reg-
ulated by each selected miRNA.
2.6. Statistical Analysis. Clinical and Q-RT data were
expressed asmean ± SE. Student’s 𝑡-test was used for compar-
ison between the two groups. For correlation analysis,
Pearson’s coefficient of correlation (𝑅2) was calculated, and
analysis of variance followed by a Student’s 𝑡-test was used. 𝑃
values ≤ 0.05 were considered significant.
3. Results
3.1. Characteristics of the Study Population. The characteris-
tics and the main clinical parameters of patients, available
in the clinical databank, are summarized in Table 1. LVAD
implanted patients were supported for a mean period of 357
days (SE = 66 days). For LVAD implanted patients, mean
clinical values measured before the device implant and at
the LVAD explant (at the time of heart transplantation) are
reported. Although patients in both groups were diagnosed
with end-stage heart failure, HTx-LVAD patients showed
generally worse baseline clinical parameters compared to
HTx-CTRL patients, justifying the requirement for LVAD
support due to unstable clinical conditions (Table 1).
Individual data of patients are shown in Figure 1. LVAD
support induced a significant increase in the off-pump
cardiac index (𝑃 < 0.05). During LVAD support a decrease
in LV end-systolic and end-diastolic volumes and in end-
diastolic diameter (𝑃 < 0.05) has been detected, togetherwith
a reduction of the plasmatic levels of NT-proBNP (𝑃 < 0.01).
However, a variable response to mechanical unloading has
been observed, with some patients clearly demonstrating an
improvement in functional parameters after LVAD support
period, while others reporting only a slight change or in some
cases even worse data (Figure 1).
3.2. miRNA Expression Profiling. In order to get a deeper
insight into the molecular mechanisms that are affected by
LVmechanical unloading and that could be associated with a
potential recovery of heart functionality, miRNA expression
profile in LV specimens collected at the moment of heart
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Figure 1: Clinical parameters of individual patients. (a) CI: cardiac index (off-pump); (b) PCWP: pulmonary capillary wedge pressure; (c)
LVEF: left ventricular ejection fraction; (d) LVESV: left ventricular end-systolic volume; (e) LVEDV: left ventricular end-diastolic volume; (f)
LVEDD: left ventricular end-diastolic diameter; (g) PASP: pulmonary artery systolic pressure; (h) PADP: pulmonary artery diastolic pressure;
(i) NT-proBNP: N-terminal prohormone of brain natriuretic peptide. For patients belonging to HTx-LVAD group, available measurements
before implantation of assistance device (pre-LVAD) and before heart transplant (post-LVAD) are shown. Statistical significance is calculated
according to Student’s 𝑡-test (∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001). In the HTx-LVAD group, paired 𝑡-test is used to compare pre-LVAD and
post-LVAD values.
transplantation from HTx-LVAD and HTx-CTRL patients
was compared.
From the heart tissue samples (30–120mg), an average
total RNA concentration of about 400 ng/𝜇L (interquartile
range 200 ng/𝜇L) was obtained in RNA eluates. After total
RNA extraction, deep sequencing was performed to obtain
a complete profile of miRNA expression. Overall, an average
of 19 million (range: 7–33 million) clean reads of 50 bp was
obtained from each sample sequencing. After preprocessing
and filtering steps, 11 million (range: 5–23million per sample)
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Figure 2: Sample clustering based on sequenced microRNA profiles. Variance-stabilizing transformed count data was used for all samples.
The heat map shows a greyscale false colour representation of the Euclidean distance matrix, and the dendrogram represents a hierarchical
clustering. Separately, HTx-CTRL and HTx-LVAD samples show a good degree of similarity and group together with the exception of HTx-
LVAD (3) and HTx-CTRL (2), which were excluded from downstream analysis.
of reads mapped to mature miRNA sequences annotated in
miRBase release 20. On the whole, more than 1700 unique
microRNA sequences were detected in heart tissue.
For each sample, miRNA expression profile was built
by counting the number of sequenced reads for each iden-
tified miRNA that is present in miRBase v.20 (see Section 2
for more details). In order to retrieve insight into group simi-
larities, sample relations were then investigated bymeasuring
the Euclidean distance between the miRNA expression pro-
files, followed by hierarchical clustering. Resulting heat map
(Figure 2) shows that the miRNA expression profiles well
distinguished betweenHTx-LVAD- andHTx-CTRL samples,
despite their wide intrinsic variability. Only samples from 2
patients, HTx-LVAD (3) and HTx-CTRL (2), clustered into
inverted group suggesting they could potentially confound
our assay. HTx-LVAD (3) patient, who was transplanted in
emergency due to sepsis coming from the LVAD driveline,
was implanted after a long history of heart failure and did
not show any improvement of functional parameters after the
period of LVAD support. HTx-CTRL (2) patient, due to a
Hodgkin lymphoma 12 years before transplant, received radio
and chemotherapy treatments which may have modified
molecular responses of the failing heart. For these reasons,
these samples have been excluded from downstream analysis.
An analysis ofmiRNA relative expression levels in the two
groups, thus including 8 samples in the HTx-CTRL group
and 7 samples in the HTx-LVAD group (after the exclusion
of the two outlier patients above specified), was then per-
formed. A total of 23microRNAs appeared to be differentially
expressed (DE), and among these 13 were found upregulated
and 10 downregulated, in the HTx-LVAD group with respect
to the HTx-CTRL group. The DE miRNAs, starting from
those with the highest abundance, are listed in Table 2.
3.3. Validation of MicroRNA Expression by Real-Time PCR.
Quantitative real-time PCR was performed to validate
sequencing results on a small set of DE miRNAs, selected
on the basis of the high expression level as well as on the
apparent relevance in heart disease according to literature
[23–29]. Specifically, miR-142-5p and -3p, miR-29b-3p, miR-
223-3p, and miR-135a-5p were chosen for validation test
in a subgroup of HTx-CTRL (𝑛 = 5) and HTx-LVAD
(𝑛 = 7) patients. Figure 3 shows the relative expression
levels as determined by Q-RT experiments for each of the
five microRNAs (Figure 3(a)), and the correlation analyses
between (log10)-transformed miRNA read counts obtained
by NGS and the correspondent relative expression values
calculated byQ-RT (Figure 3(b)). Q-RT values appeared to be
significantly correlated with sequencing data for all the tested
microRNAs (Figure 3(b)), thus sustaining the accuracy and
reliability of NGS analysis. For some of the selected miRNAs
(miR-142-3p, miR-223-3p, and miR-135a-5p), a significant
difference in expression level between HTx-CTRL and HTx-
LVAD patients was also confirmed by Q-RT (Figure 3(a)).
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Table 2: List of differentially expressed (DE) miRNAs in LVAD-supported versus “control” failing explanted hearts.
miRNA HTx-CTRL HTx-LVAD FC 𝑃 value 𝑃 adjusted
hsa-miR-29b-3p 5421 3156 0.58 1.11𝐸 − 03 3.54𝐸 − 02
hsa-miR-142-5p 4417 9146 2.07 2.33E − 04 9.28E − 03
hsa-miR-4485 3066 329 0.11 6.19𝐸 − 25 6.41𝐸 − 22
hsa-miR-374b-5p 2429 1382 0.57 1.16𝐸 − 03 3.54𝐸 − 02
hsa-miR-4532 2250 833 0.37 3.91𝐸 − 07 2.70𝐸 − 05
hsa-miR-4792 979 412 0.42 2.90𝐸 − 06 1.76𝐸 − 04
hsa-miR-338-3p 936 1536 1.64 2.25E − 03 5.67E − 02
hsa-miR-144-5p 873 1465 1.68 5.97E − 04 2.13E − 02
hsa-miR-223-3p 669 1947 2.91 2.06E − 10 2.67E − 08
hsa-miR-135a-5p 593 161 0.27 6.63𝐸 − 14 1.14𝐸 − 11
hsa-miR-142-3p 498 913 1.83 1.70E − 03 4.51E − 02
hsa-miR-335-3p 452 756 1.67 2.25E − 04 9.28E − 03
hsa-miR-4284 210 31 0.15 3.28𝐸 − 19 8.49𝐸 − 17
hsa-miR-376a-3p 184 75 0.41 1.42𝐸 − 05 6.66𝐸 − 04
hsa-miR-3195 159 85 0.53 9.46𝐸 − 04 3.16𝐸 − 02
hsa-miR-378g 137 271 1.98 2.33E − 03 5.69E − 02
hsa-miR-628-5p 109 193 1.77 1.32E − 03 3.91E − 02
hsa-miR-5683 98 415 4.23 1.26E − 19 4.36E − 17
hsa-miR-146b-3p 88 251 2.85 4.95E − 06 2.85E − 04
hsa-miR-23a-5p 67 119 1.77 2.96E − 03 6.64E − 02
hsa-miR-27a-5p 61 126 2.05 9.06E − 05 3.91E − 03
hsa-miR-4461 58 118 2.04 2.42E − 03 5.69E − 02
hsa-miR-216a-5p 50 8 0.17 5.30𝐸 − 13 7.84𝐸 − 11
Differentially expressed miRNAs are ranked according to the number of read counts. Upregulated and downregulated miRNAs are, respectively, shown in bold
and white lines. FC = fold change.
In other two cases (miR-142-5p and miR-29b-3p), the results
indicated a clear consistence with sequencing data, although
a statistical significance was not reached probably due to
the reduced number of samples used in PCR experiments
(Figure 3(a)).
3.4. Association between MicroRNA Expression and Clinical
Parameters. Besides sequencing data validation, a further
analysis has been made in order to check a possible associa-
tion between the expression of specificmicroRNAs, identified
as differentially regulated in LVAD-supported patients, and
their clinical parameters, indicative of heart function.
As shown in Table 1 and Figure 1, there is not a clear
distinction in the majority of hemodynamic and echocar-
diographic parameters measured in patients without and
with LVAD support period, because of the worse clinical
conditions of HTx-LVAD patients at baseline as well as the
interindividual variability in response to LVAD. For these
reasons, the association analysis has been limited to the
cardiac index, which appeared to be significantly improved in
LVAD implanted group with respect to HTx-CTRL patients
(2.82 ± 0.30 versus 1.90 ± 0.17 L/min/m2, 𝑃 < 0.05) (Table 1).
As shown in Figure 4, correlation analysis documents
a significant association among cardiac index values and
expression of some microRNAs (calculated on the basis
of number of read counts). In fact, a positive correlation
is present with some upregulated miRNAs in HTx-LVAD
group: miR-338-3p (𝑟 = +0.694, 𝑃 = 0.006), miR-142-5p
(𝑟 = +0.686,𝑃 = 0.007),miR-223-3p (𝑟 = +0.628,𝑃 = 0.016),
miR-142-3p (𝑟 = +0.627, 𝑃 = 0.016), miR-27a-5p (𝑟 =
+0.603, 𝑃 = 0.022), and miR-378g (𝑟 = +0.560, 𝑃 = 0.037).
Differently, miR-216a-5p, which is downregulated in LVAD
group, appears negatively associated with the cardiac index
(𝑟 = −0.643, 𝑃 = 0.013).
It is important to underline that in the LVAD-supported
group the patients who did not demonstrate a recovery in
cardiac function and maintained a low cardiac index even
after mechanical assistance showed also a correspondence
in miRNA expression levels similar to HTx-CTRL patients
(Figure 4).
Moreover, other associations among patients’ hemody-
namics and miRNA expression were found in relation to
pulmonary vascular resistance, calculated as ratio between
pulmonary artery pressure and cardiac output values. From
clinical database these measurements were available only for
patients of the HTx-CTRL group. As shown in Figure 5, a
significant positive correlation is present with miR-29b-3p
(𝑟 = +0.873, 𝑃 = 0.005) and miR-374b-5p (𝑟 = +0.722,
𝑃 = 0.04), two miRNAs which were found highly expressed
in heart (Table 2). Both miRNAs appear to be downregulated
in LVAD-supported patients compared to the control group
(Table 2).
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Figure 3: Validation by Q-RT PCR and correlation with next generation sequencing data. (a) Mean Q-RT PCR normalized expression values
of selectedmicroRNAs in a subset of HTx-CTRL (𝑛 = 5, grey bars) andHTx-LVAD (𝑛 = 7, white bars) heart samples (∗𝑃 < 0.05; ∗∗𝑃 < 0.01).
(b) Correlation analyses between (log10)-transformed number of miRNA read counts and Q-RT PCR relative expression values. Grey and
white symbols are representative of HTx-CTRL and HTx-LVAD data pairs, respectively.
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Figure 4: Expression of differentially regulated miRNAs in LVAD-supported patients is associated with cardiac index. The graphs show the
correlation analyses between (log10)-transformed number of miRNA read counts and individual measurements of cardiac index in HTx-
CTRL (grey symbols, 𝑛 = 9) and HTx-LVAD patients (white symbols, 𝑛 = 5).
3.5. In Silico Identification of Putative miRNA Targets and
Pathway Enrichment Analysis. The subset of DE microRNAs
showing association with cardiac index (miR-338-3p, miR-
142-5p and -3p, miR-216a-5p, miR-223-3p, miR-27a-5p, miR-
378g) or with pulmonary vascular resistance values (miR-
29b-3p and miR-374b-5p) was further analyzed through
bioinformatic tools in order to identify putative targets
of miRNA regulation and relative pathways enrichment.
Prediction of miRNA targets by using DIANA-microT-CDS
algorithm and applying a 0.9 cut-off threshold (considered
as stringent) [21] revealed a total of 353 putative targets for
miR-374b-5p, 350 formiR-29b-3p, 324 formiR-142-5p, 261 for
miR-338-3p, 160 for miR-223-3p, 145 for miR-142-3p, 135 for
miR-216a, 128 for miR-378g, and 14 for miR-27a-5p. Putative
targets of all miRNAs in the subset were then analyzed as a
whole to identify the most enriched pathways, as annotated
in KEGG database. The complete list of enriched pathways
with candidate target genes, ranked according to the number
of miRNAs predicted to regulate each pathway and to the
significance value calculated by mirPath software, is reported
in SupplementaryTable 1 in SupplementaryMaterial available
online at http://dx.doi.org/10.1155/2014/592512. Among this
list, most representative pathways possibly involved in heart
function or altered in cardiac disease states are highlighted in
Table 3. Remarkably, as shown in the table, several pathways
connected with regulation of cellular biomechanics or with
different kinds of cardiomyopathies, such as regulation of
actin cytoskeleton (with candidate target genes representing
13.5% of total genes annotated in the pathway), focal adhe-
sion (19.3%), dilated cardiomyopathy (16.7%), Wnt signaling
pathway (14.4%), hypertrophic cardiomyopathy (16.9%), and
ECM (extracellular matrix-) receptor interaction (26.4%),
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Figure 5: Expression of downregulated miRNAs is associated with pulmonary vascular resistance values in failing transplanted hearts.
The graphs show the correlation analyses between (log10)-transformed number of miRNA read counts and individual measurements of
pulmonary vascular resistance, expressed in Wood units (WU), in HTx-CTRL patients (𝑛 = 8).
Table 3: Representative enriched KEGG pathways, involved in heart function or disease, according to in silico analysis of predicted targets
of miRNAs associated with clinical parameters in failing heart with/without LVAD support.
KEGG pathway 𝑃 value Number of miRNAs Number of target genes (%in the pathway)
Regulation of actin cytoskeleton 1.44𝐸 − 04 9 29 (13.5%)
Focal adhesion 1.37𝐸 − 16 8 40 (19.3%)
PI3K-Akt signaling pathway 1.15𝐸 − 11 8 50 (14.4%)
mTOR signaling pathway 9.89𝐸 − 06 8 13 (21.7%)
Dilated cardiomyopathy 5.46𝐸 − 05 8 15 (16.7%)
Wnt signaling pathway 6.04𝐸 − 05 8 20 (14.4%)
Hypertrophic cardiomyopathy (HCM) 7.65𝐸 − 05 8 14 (16.9%)
Arrhythmogenic right ventricular cardiomyopathy 1.77𝐸 − 03 8 13 (17.6%)
ECM-receptor interaction 3.21𝐸 − 53 7 23 (26.4%)
MAPK signaling pathway 1.39𝐸 − 06 7 36 (14.0%)
Cytokine-cytokine receptor interaction 5.73𝐸 − 03 7 24 (9.1%)
TGF-beta signaling pathway 9.21𝐸 − 06 6 16 (20.0%)
Adherens junction 4.53𝐸 − 04 6 11 (15.1%)
Phosphatidylinositol signaling system 3.51𝐸 − 03 5 12 (14.8%)
appear among themost regulated pathways by the network of
the most relevant miRNAs identified in the study (Table 3).
Similar results were also obtained by applying TargetScan
context score and evolutionary conservation score algorithms
for miRNA target prediction followed by overrepresentation
analysis in ConsensusPathDB software (data not shown), to
further support the possible involvement of thesemicroRNAs
in molecular processes of LVAD-induced heart recovery.
4. Discussion
The aim of the study was to exploit a comparison of
microRNA modulation in end-stage HF patients who went
to transplantation directly or after a period of LVAD support
in order to investigate the effects of a mechanical unloading
period as well as the potential molecular mechanisms under-
lying cardiac remodeling. miRNAs can be indeed powerful
tools of diagnostic information, either for their extraordinary
variability of expression across different physiological and
pathological states or for their ability to regulate a large
number of target messengers. A next generation sequencing
approach has been chosen to have a complete coverage of
miRNA profiling and, although the analysis was performed
on a limited number of severely ill patients, it reveals
significant differences in the patterns of miRNA expression
in failing hearts supported or not with LVAD.
The main limit of the study is due to the retrospective
nature of the analysis: in fact, only few data, not planned in
a specific well defined protocol with timing, are available in
the clinical databank, even if there was the authorization of
the local ethics committee for tissue samples at the trans-
plantation time. No apex at the time of LVAD implantation
was available, in order to allow an internal control analysis.
Despite this relevant lack in the materials and methods,
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the miRNA profiles are capable of distinguishing between the
two groups.
Two recent papers have used the NGS approach to
compare the miRNA profiling in human heart failure before
and after LVAD implantation [10, 12]. The article by Yang
et al. [12] is an extensive analysis of the coding and noncoding
transcriptome in nonfailing human LV and in failing human
LV before/after LVAD support, aimed at identifying an
RNA signature that is sensitive to hemodynamic loading
conditions as well as capable of discriminating the specificHF
etiology. The paper by Akat et al. [10] is a comparative RNA-
sequencing analysis ofmyocardial and circulatingmiRNAs in
patients with stable and end-stage HF before and at different
time points after LVAD implantation. Both studies find more
than one hundred miRNAs differentially expressed in failing
compared to nonfailing hearts, but only a restricted number
of themappear to be recovered byLVADunloading.However,
by making a comparison between the specific miRNAs
identified in the two studies, low concordance is present:
in particular, none of the miRNAs reported as significantly
affected by LVAD is common to both screenings. Differently,
in our study, miR-27a-5p, significantly upregulated in the
HTx-LVAD group of patients, is concordantly found upreg-
ulated after LVAD implantation also by Akat et al. [10]. In
addition,miR-216a, strongly upregulated both in tissue and in
plasma samples of advanced HF patients as reported by Akat
et al. [10], showed a more than fivefold decreased expression
in HTx-LVAD with respect to HTx-CTRL failing hearts in
our findings (Table 2). On the contrary, none of the miRNAs
marked as improved or normalized by LVAD in Yang et al.
[12] appeared to be significantly changed in our screening,
even if in some cases a similar trend in the expression levels in
the two groups could be seen (data not shown, not significant
difference).
However, it is important to stress that the present study,
which utilizes a case-control approach and no paired samples,
is focused on the research of miRNAs which are modified
by LVAD presence. Since miRNAs are considered important
tools for maintaining the cell/tissue/organ homeostasis, their
change, considered as “normalization,” might not necessarily
be expression of cardiac recovery, but in some cases their
“deregulation” might also be signal of a reactive response to a
disequilibrium state.
A particularly important finding of this study is that
the expression level of some of the identified miRNAs is
correlated with the improvement of cardiac index (Figure 4).
In the enrolled population, cardiac index (assessed before
LVAD implant and off-pump during heart transplant) is the
hemodynamic parameter that better differentiates improve-
ment in heart function before and after LVAD support
(Table 1). This correlation supports the role of DE miRNAs
identified in this screening in cardiac remodeling. In line
with this observation, patients who did not recover a cardiac
function after LVAD implantation apparently clustered with
the HTx-CTRL group (Figure 4). It is worth noting that
patients implanted with LVAD had in general worse cardiac
parameters compared to the HTx-CTRL group: in fact, an
acute phase in patients included in the waiting list for heart
transplantation requires an urgent assistance by mechanical
support, as suggested by the guidelines, and the worse clinical
condition at the LVAD implantation time is a consequence
of the disease unstable state. For this reason, although LVAD
implantation induced an improvement in cardiac parameters
(see Table 1), some values are still worse in patients after
LVAD than inHTx-CTRLpatients.These considerations sug-
gest that miRNAs modulated by LVAD implantation might
indicate the activation of reverse remodeling processes (such
as the cytoskeleton-mediated remodeling, see the following)
more than representing amarker of the contractility recovery
level. In line with our interpretation, 14 miRNAs, out of
the 23 selected in the study, were also previously identified
as differentially modulated in fetal myocardium compared
to nonfailing postnatal hearts [10]. The expression of 10
out of the “fetal” miRNAs appears to be reversed in HTx-
LVAD patients, further supporting the hypothesis of reverse
remodeling markers. In addition, by considering the positive
correlation between the expression levels of miR-29b-3p
and miR-374b-5p and the highest pulmonary resistances in
the control group (Figure 5), the downregulation of these
miRNAs in LVAD patients could play a role in a possible
pulmonary resistance decrease after mechanical unloading.
Some of the identified miRNAs have been already
described in heart failure or in other cardiovascular diseases.
One of the most interesting is miR-142, whose 5p and
3p pre-miRNA strands are both expressed at high level
in the performed analysis. Both miR-142-5p and -3p were
upregulated about twofold in tissues from LVAD patients, as
documented by data reported in Table 2, and their expression
was correlated with cardiac index (Figure 4). Altered levels of
thesemiRNAs in bloodwere previously indicated as potential
biomarkers for diagnosis of dilated cardiomyopathy andheart
failure [24, 28, 29]. However, this study highlights for the
first time that these two miRNAs are modulated in cardiac
tissues of LVAD patients. Downregulation of miR-142-5p and
-3p has been described in cardiac hypertrophy [30, 31], and a
role of these miRNAs as repressors of components of the NF-
kB pathway, preventing cytokine-mediated NO production,
is suggested [30]. Sarcomeric genes emerged as potential
targets of members of the miR-142 family, and modulation
of 𝛼-actinin has been experimentally demonstrated [30].
Indeed, genes of the integrin signaling network connecting
membrane and cytoskeleton are also among the pathways
identified by genome sequencing as genes associated with
functional recovery of end-stage heart failure [32].
A twofold increased expression in LVAD-supported
patients was also detected for miR-378 (Table 2), a cardiom-
yocyte-enriched miRNA which has been reported to act as
an endogenous negative regulator of cardiac hypertrophy, and
whose levels are downregulated during hypertrophic growth
and heart failure [33, 34]. The importance of miR-378 in HF-
induced cardiac remodeling is supported by the observation
that (a) deficiency of miR-378 alone is sufficient to induce
fetal gene expression [34] and (b) compensation of miR-
378 loss, through adeno-associated virus (AAV) mediated
cardiomyocyte-targeted expression, partially prevents left
ventricular hypertrophy and improves cardiac function in
an in vivo model of cardiac pressure overload by thoracic
aortic constriction [33]. These data could be therefore in line
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with the observed increase in miR- 378 expression in patients
showing a positive response to LVAD implantation.
MiR-216a and miR-29b are detected among miRNAs
which exhibit a downregulation in cardiac tissues of LVAD
patients. MiR-216a was already identified as strongly upreg-
ulated in cardiac biopsies from HF patients and positively
controlled by TGF-𝛽 [10, 25]. Concerning miR-29b, the
observed downregulation is instead in line with data reported
by Matkovich et al. [8] in LVAD-supported heart. The
three members of the human miR-29 family have been
extensively analyzed in human and animal models for their
strong antifibrotic effect in heart and other organs. These
miRNAs are indeed predicted to target at least 16 extracellular
matrix genes [35]. Other studies have instead indicated that
reduction of miR-29 might be cardioprotective by reducing
myocardial infarct size and apoptosis in heart subjected to
ischemia/reperfusion injury [36].Moreover,miR-29 has been
shown to modulate de novo DNA methyltransferase in car-
diac tissues, suggesting that a role in epigenetic modifications
could contribute to cardiac remodeling [37].
The in silico analysis performed to identify putative
miRNA targets and the enriched associated pathways reveals
several pathways involved in regulation of actin cytoskeleton,
focal adhesion, ECM-receptor interaction, and adherens
junction (Table 3). The cytoskeleton provides a structural
framework for the cell, serving as a scaffold that deter-
mines the cell shape and the general organization of the
cytoplasm [38]. Embedded within the cytoskeleton, special-
ized protein structures such as adherens junction and focal
adhesion proteins, related to the integrin signaling, facilitate
the communication between the cytoskeleton and, respec-
tively, the neighbouring cells or the ECM [39–41]. Recent
data clearly demonstrate that cytoskeleton and its related
protein complexes regulate many other processes within
the cell, including signaling, excitability, impulse propaga-
tion, contractility, and gene expression. Therefore, the cyto-
skeleton acts as a signal integrator for mechanical and
structural inputs, and it is supposed to play a pivotal role
in myocyte adaptive or maladaptive remodeling processes
during physiological growth or pathological conditions. The
identification of many genes belonging to these pathways
as putative targets of the miRNAs modulated in LVAD
patients suggests the involvement of cytoskeleton-mediated
remodeling in the recovery process stimulated by LVAD,
despite the severe degree of disease in patients at the end stage
of heart failure. In line with this hypothesis, a microarray
analysis, performed on a small number of patients before and
after LVAD implantation, revealed a significant association of
integrin signaling pathway with recovery [32].
Moreover, among the most regulated pathways by the
subset of miRNAs identified in the presented analysis, PI3K-
Akt and mTOR signaling pathways can also be importantly
involved in mechanisms controlling the progression of heart
failure [42], while theWnt signaling pathway, normally regu-
lating cardiogenesis during the development, can be induced
in adult heart during maladaptive myocardial remodeling
[43].
It is also interesting to note that some of the identified
miRNAs have been already detected in the plasma of patients
with different kind of cardiovascular diseases [10, 23, 27–29].
Although the levels of circulating miRNAs not always reflect
the relative level in tissues, it is tempting to hypothesize that
thesemiRNAs have the potential to become novel biomarkers
of remodeling processes. A further research is planned in
this direction, by considering the potential, future increase
of LVAD implantation as partial support and/or temporary
mechanical unloading in less severe degree of heart failure,
with a possible aim of inducing native heart recovery.
5. Conclusions
Despite the limited number of patients together with the
retrospective nature of the study, the presentmiRNAprofiling
allowed identifying a set of differentially modulated miRNAs
in heart tissues of LVAD-supported end-stage heart failure
patients. The correlation between the expression level of
several of them and hemodynamic functional parameters
suggests that dynamic changes in specific miRNAs can be
indicative of a recovery process after mechanical unloading.
Potential targets of miRNA modulation are implicated in
pathways regulating cytoskeleton and interaction with the
extracellularmatrix, to support the idea that the cytoskeleton,
by triggering a wide range of cellular functional responses,
might play a pivotal role in guiding the recovery process.
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